BCDA today
$0.94+$0.02 (+2.53%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourStrong Bullish
1 hourLeaning Bullish
15 minLeaning Bullish
5 minConsolidating
Daily trend turns down below $0.75
Key levels
Resistance$1.11
Resistance$1.00
Support$0.84
Support$0.75
Latest news & SEC filings
LegalBioCardia wraps up PMDA talks for its CardiAMP cell therapy
All BCDA news →About BioCardia
BioCardia develops cell-based treatments for heart and lung conditions and is still in the testing phase. Its main candidates use bone marrow cells taken from the individual being treated for ischemic heart failure and chronic myocardial ischemia, plus donor-derived mesenchymal stem cells for heart failure and acute respiratory distress syndrome. The company also makes the Helix catheter system for delivering biologic agents into heart muscle and offers it to outside partners. Operations are based in the United States.
Based on the company's 10-K filed Mar 24, 2026.
Nasdaq · Healthcare
BioCardia, Inc. (BCDA)
What Is the Price Target for BCDA?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is BCDA a Buy or Sell Right Now?
Thesis
- •Revenue growing -87.8% YoY with UNKNOWN trend — consistent growth.
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for BCDA.
Start Free Trial →Is BCDA Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/B, PEG
Fair Value
$0.99
5
Moat Score
NONE
2/9
Piotroski Score
-75.3
Altman Z-Score
What Is Smart Money Doing with BCDA?
Insider Signal
BUYING
13 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Altman Peter | director officer | Buy | 300 | $285.00 | Oct 16, 2026 |
| Altman Peter | director officer | Buy | 200 | $190.00 | Oct 15, 2026 |
| Altman Peter | director officer | Buy | 1,000 | $1K | Sep 29, 2026 |
| Altman Peter | director officer | Buy | 1,900 | $2K | Sep 23, 2026 |
| Altman Peter | director officer | Buy | 5,000 | $4K | Jun 9, 2026 |
| Altman Peter | director officer | Buy | 1,500 | $1K | May 20, 2026 |
| Altman Peter | director officer | Buy | 200 | $190.00 | May 19, 2026 |
| Altman Peter | director officer | Buy | 5,700 | $5K | May 18, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →BCDA Growth Story
Revenue YoY
-87.8%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
5.7%
Revenue Trend
UNKNOWN
Dark Pool Trades for BCDA
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for BCDA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:33:49 | $0.94 | 1,000 | $$945 | BUY |
| 20:57:11 | $0.94 | 1,500 | $$1K | BUY |
| 19:54:41 | $0.94 | 2,945 | $$3K | BUY |
| 19:14:31 | $0.94 | 4,200 | $$4K | BUY |
| 19:14:31 | $0.94 | 4,200 | $$4K | BUY |
5 dark pool trades shown · $$13K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for BioCardia, Inc. (BCDA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →BCDA — frequently asked questions
What is BCDA stock price today?
BioCardia, Inc. (BCDA) is at $0.94, up 2.53% (+$0.02) at the Nov 12, 2026 close.
Why is BCDA stock moving today?
Latest BCDA news — Nov 6, 2026: BioCardia wraps up PMDA talks for its CardiAMP cell therapy
What do analysts rate BCDA?
Analyst ratings for BCDA: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
Did BCDA beat earnings?
BCDA last reported on Aug 12, 2026: EPS -$0.13 vs -$0.18 expected — a beat of 27.8%.
Does BCDA pay a dividend?
BCDA does not currently pay a dividend.
What are BCDA support and resistance levels?
Support: $0.84, $0.75. Resistance: $1.00, $1.11, $1.23.
What are insiders doing with BCDA?
Insider activity: BUYING, 13 buys and 0 sells in the last 90 days.
What is the latest news on BCDA?
Nov 6, 2026: BioCardia wraps up PMDA talks for its CardiAMP cell therapy